[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jade Biosciences Inc (JBIO)

Jade Biosciences Inc (JBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 836,158
  • Shares Outstanding, K 49,360
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,410 K
  • EBIT $ -154 M
  • EBITDA $ -154 M
  • 60-Month Beta 1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.95

Options Overview Details

View History
  • Implied Volatility 124.47% (+20.53%)
  • Historical Volatility 81.73%
  • IV Percentile 5%
  • IV Rank 7.78%
  • IV High 485.44% on 09/15/25
  • IV Low 94.02% on 11/17/25
  • Expected Move (DTE 11) 0.64 (3.76%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 106
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 8.96
  • Today's Open Interest 1,694
  • Open Int (30-Day) 1,636
  • Expected Range 16.30 to 17.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 4
  • High Estimate $-0.60
  • Low Estimate $-0.79
  • Prior Year $-0.86
  • Growth Rate Est. (year over year) +23.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.93 +6.34%
on 06/04/26
26.83 -36.86%
on 05/11/26
-8.32 (-32.94%)
since 05/05/26
3-Month
12.91 +31.22%
on 03/24/26
28.00 -39.50%
on 04/27/26
+3.06 (+22.05%)
since 03/05/26
52-Week
6.57 +158.04%
on 06/13/25
28.00 -39.50%
on 04/27/26
+10.05 (+145.86%)
since 06/05/25

Most Recent Stories

More News
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.94 (-4.51%)
Jade Biosciences Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.94 (-4.51%)
Jade Biosciences Announces Proposed Underwritten Public Offering

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.94 (-4.51%)
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody...

JBIO : 16.94 (-4.51%)
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

~70% IgA reductions sustained at 12 weeks after a single dose of JADE101 >70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeks IgA-lowering...

JBIO : 16.94 (-4.51%)
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA...

SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.94 (-4.51%)
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology  JADE201...

JBIO : 16.94 (-4.51%)
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Interim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq:...

JBIO : 16.94 (-4.51%)
JBIO's Phase One Whisper Number Already Assumes Perfect Execution Nobody's Earned Yet

Barchart Research What to Expect from JBIO Earnings JBIO Generated May 7, 2026 Current Price $24.22 EPS Estimate $$-0.52 Consensus Rating Strong Buy Average Move 3.06% JBIO's Phase One Whisper Number Already...

JBIO : 16.94 (-4.51%)
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress  Phase 2 trial of JADE101 in IgA nephropathy patients expected to...

JBIO : 16.94 (-4.51%)

Business Summary

Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 19.66
2nd Resistance Point 18.95
1st Resistance Point 17.94
Last Price 16.94
1st Support Level 16.22
2nd Support Level 15.51
3rd Support Level 14.50

See More

52-Week High 28.00
Fibonacci 61.8% 19.81
Fibonacci 50% 17.28
Last Price 16.94
Fibonacci 38.2% 14.75
52-Week Low 6.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.